R-Tech Ueno: Announcement of the Execution of a License Agreement for Unoprostone by EON


More Info
									R-Tech Ueno: Announcement of the Execution of a
License Agreement for Unoprostone
March 23, 2011 05:03 AM Eastern Daylight Time 

TOKYO--(EON: Enhanced Online News)--R-Tech Ueno, Ltd. (RTU) (JASDAQ:4573) today announced that
RTU and Sucampo Manufacturing and Research AG (SMR), a wholly owned subsidiary of Sucampo
Pharmaceuticals, Inc. (NASDAQ:SCMP) (Sucampo), executed a License Agreement to develop, manufacture, and
commercialize Unoprostone (Rescula®) in regions excluding Japan, Taiwan, Republic of Korea, the People's
Republic of China and North America (the SMR territory).

(1) Background to this Agreement
Upon termination of our License Agreement with Novartis Pharma AG (refer to the press release dated July 2nd,
2010), we had sought for a new licensee to maximize business profit from Unoprostone, and signed this Agreement.

(2) Overview of the Agreement
Under the terms of this license agreement, SMR holds exclusive rights to develop, use, make, have made, export,
commercialize, promote, offer for sale and sell Unoprostone in all countries except in SMR Territory for its
approved indication, the treatment of glaucoma and ocular hypertension. Also under this agreement, SMR has
gained the right to develop Unoprostone for additional ophthalmic indications as well as rights to all associated
patents and other intellectual property associated with Unoprostone in SMR territory.
RTU receives an upfront payment of 3 million US dollars from SMR upon execution of the agreement. RTU will also
receive additional milestone payments based on the achievement of specified development and commercialization

(3) About the contracting party
SMR is a wholly-owned subsidiary of Sucampo Pharmaceuticals, Inc.

(4) Effect on our performance
We believe the above Agreement will not bring effect on our full-year performance forecast released on August
12th, 2010.

The President of RTU, Yukihiko Mashima, M.D., PhD, said, "In April 2009 we have already licensed the rights for
the commercialization of Unoprostone in the North America region to Sucampo, which aims to market Unoprostone
as a treatment for atrophic age-related macular degeneration. We are very pleased that this agreement with
Sucampo, with its thorough knowledge of Unoprostone, will further enhance Unoprostone value beyond Glaucoma
and Ocular Hypertension. We are focused on the development of new drugs for unmet medical needs, and we
believe that Unoprostone will contribute to the Quality of Life (QOL) of a wide population of patients."

The Chief Executive Officer and Chairman of Sucampo, Dr. Ryuji Ueno, M.D., Ph.D., Ph.D. , said, "We are very
excited about this agreement, as we believe that unoprostone isopropyl has significant potential in several markets. It
is already approved in the United States, Japan and some European countries as a treatment for Glaucoma and
Ocular Hypertension. We will move forward to reactivate the licenses in Switzerland and the European Union for
Glaucoma and Ocular Hypertension as we continue our efforts to achieve a scientifically accurate and updated
supplemental new drug application label in the U.S. We will, at the same time, pursue additional indications such as
dry AMD and Retinitis Pigmentosa. Unoprostone isopropyl has shown new potential in Retinitis Pigmentosa patients
in an RTU-sponsored trial that showed a dose-dependent improvement in retinal sensitivity after only six months of
treatment. This alliance insures state of the art global development and commercialization between the Sucampo
family of companies and R-Tech Ueno for all current and potential indications. If unoprostone isopropyl is
successfully developed for these additional indications, it will increase our ability to fulfill our mission of offering
significant new therapeutic options to ophthalmology patients."

About R-Tech Ueno, Ltd.

R-Tech Ueno is a bio venture company established in September 1989 for the purpose of R&D and marketing of
drugs. Under leadership of the CEO, also a medical doctor, the company is developing new drugs on the theme
"Physician-Oriented New Drug Innovation", targeting ophthalmologic and dermatologic diseases that previously had
no effective therapeutic agent.
We aim at becoming a "global pharmaceutical company specializing in specific fields (ophthalmology and
dermatology) and developing pharmaceutical products through the eyes of doctors and selling." We are promoting
development of new drugs of unmet medical needs (medical needs that are not fulfilled yet) which the government
recommends and assists, orphan drugs and the drugs in the field of anti-aging (lifestyle drugs).

About Unoprostone

Rescula®(Unoprostone) Eye Drops 0.12% was developed by RTU, and is the world's first prostone-based
treatment for glaucoma and ocular hypertension. Rescula® Eye Drops 0.12% has a pharmacological effect as an ion
channel opener. There are reports that Rescula® Eye Drops 0.12% has not only an ocular pressure decreasing
action but also an optic nerve protective action (in vitro) and an action to improve ocular blood flow in normal
tension glaucoma. It has been approved in 45 countries all over the world since it was marketed in 1994. In 2009,
due to formulation change, the concentration of the preservative (benzalkonium chloride) which is reported to cause
various adverse reactions has been greatly reduced using our unique technique.
RTU is promoting the development of a neuroprotective drug based on Unoprostone (product name Ocuseva TM)
Eye drop 0.15%, and a phase II clinical trial was completed. The results of the phase II clinical trial showed that the
product significantly reduced the number of patients with deteriorating retinal sensitivity in the central part of the
ocular fundus.

About Retinitis Pigmentosa

Retinitis pigmentosa is a hereditary disease and its prevalence rate is said to be about 1 in 5000 people in the world
and 1 in 4000 - 8000 people in Japan. When this number is applied to the population of Japan, 128 million people,
the number of patients with retinitis pigmentosa can be estimated as 16,000 - 32,000 people which makes this
disease an orphan disease. On the other hand, when projecting the number of patients with retinitis pigmentosa in the
world from the world population, 6.75 billion people (2008), it can be estimated as 1.35 million people. When
retinitis pigmentosa progresses, patients suffer progressive night blindness, where it becomes difficult to see in dim
light, or visual field constriction and then deterioration of vision. In the end stage, they may suffer from severe visual
loss or even blindness. It is designated as an intractable disease and appropriate therapeutic drugs or therapeutic
methods have not been established at the moment.

About Age-related Macular Degeneration

More than 8 million people are affected by age-related macular degeneration (AMD) in the U.S. AMD is a disease
that affects the retina, leading to vision loss. AMD is the No.1 cause of vision loss in adults worldwide. It is
estimated that the prevalence in the U.S. will increase by more than 50% by 2020, and that the number of patients
will amount to approximately 12 million. Approximately 80 to 90% of the patients have an atrophic form of AMD,
for which there is no approved treatment at present.

About Sucampo Pharmaceuticals, Inc.

Sucampo Pharmaceuticals, Inc., an international pharmaceutical company based in Bethesda, Maryland, focuses on
the development and commercialization of medicines based on prostones. The therapeutic potential of prostones,
which occur naturally in the human body by enzymic, 15-PGDH, transformation of certain fatty acids, was first
identified by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo Pharmaceuticals' Chairman and Chief Executive Officer.
Dr. Ueno founded Sucampo Pharmaceuticals in 1996 with Kuno, Ph.D., founding Chief Executive Officer and
currently Advisor, International Business Development and a member of the Board of Directors. For more
information about Sucampo Pharmaceuticals, please visit www.sucampo.com.
R-Tech Ueno, Ltd.
Koji Nakamura, +81-3-3596-8011
Business Management Department

Permalink: http://eon.businesswire.com/news/eon/20110323005584/en

To top